Long-term outcomes of combined hepatocellular-cholangiocarcinoma after hepatectomy or liver transplantation: A systematic review and meta-analysis
De-Bang Li a , Xiao-Ying Si b , Shi-Jie Wang b , Yan-Ming Zhou b , ∗
a Department III of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China
b Department of Hepatobiliary & Pancreatovascular Surgery, First Affiliated Hospital of Xiamen University, Xiamen 361003, China
Abstract：Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare primary liver malignancy. We conducted a systematic review and meta-analysis to assess the evidence available on the long-term outcomes of cHCC-CC patients after either hepatectomy or liver transplantation (LT).
Data Sources: Relevant studies published between January 2000 and January 2018 were identified by searching PubMed and Embase and reviewed systematically. Data were pooled using a random-effects model.
Results: A total of 42 observational studies involving 1691 patients (1390 for partial hepatectomy and 301 for LT) were included in the analysis. The median tumor recurrence and 5-year overall survival (OS) rates were 65% (range 38%–100%) and 29% (range 0–63%) after hepatectomy versus 54% (range 14%–93%) and 41% (range 16%–73%) after LT, respectively. Meta-analysis found no significant difference in OS and tumor recurrence between LT and hepatectomy groups.
Conclusion: Hepatectomy rather than LT should be considered as the prior treatment option for cHCC-CC.
. [J]. Hepatobiliary Pancreat Dis Int, 2019, 18(1): 12-18.
Li DB, Si XY,Wang SJ, Zhou YM. Long-term outcomes of combined hepatocellular-cholangiocarcinoma after hepatectomy or liver transplantation: A systematic review and meta-analysis. Hepatobiliary Pancreat Dis Int, 2019, 18(1): 12-18.
2019, Vol. 18 
